[HTML][HTML] Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

…, MQ Lacy, SR Hayman, FK Buadi, C Colby… - Journal of Clinical …, 2012 - ncbi.nlm.nih.gov
Purpose Cardiac involvement predicts poor prognosis in light chain (AL) amyloidosis, and
the current prognostic classification is based on cardiac biomarkers troponin-T (cTnT) and N-…

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

…, RA Kyle, DR Larson, LJ Melton, CL Colby… - The Lancet, 2010 - thelancet.com
Background Monoclonal gammopathy of undetermined significance (MGUS) is defined by
expression of heavy-chain immunoglobulin (IgH) and is the precursor lesion for 80% of cases …

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

…, JA Katzmann, DR Larson, CL Colby… - Blood, The Journal …, 2010 - ashpublications.org
Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary
amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 …

Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population

…, RA Kyle, DR Larson, TM Therneau, CL Colby… - Mayo Clinic …, 2012 - Elsevier
Objective To determine whether the free light chain (FLC) assay provides prognostic
information relevant to the general population. Methods After excluding persons with a known …

Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance

…, BJ Foreman, DR Larson, CL Colby… - Blood, The Journal …, 2009 - ashpublications.org
We examined whether monoclonal gammopathy of undetermined significance (MGUS) is
increased in first-degree relatives of multiple myeloma (MM) or MGUS patients. Probands were …

Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition

…, LJ Melton III, DR Larson, JT Benson, CL Colby… - Mayo Clinic …, 2012 - Elsevier
Objectives To determine the incidence of monoclonal gammopathy of undetermined significance
(MGUS) in the general population and to estimate the duration of occult MGUS before …

[HTML][HTML] SNP interaction detection with random forests in high-dimensional genetic data

SJ Winham, CL Colby, RR Freimuth, X Wang… - BMC …, 2012 - Springer
Background Identifying variants associated with complex human traits in high-dimensional
data is a central goal of genome-wide association studies. However, complicated etiologies …

[HTML][HTML] Dissecting clinical heterogeneity of bipolar disorder using multiple polygenic risk scores

BJ Coombes, M Markota, JJ Mann, C Colby… - Translational …, 2020 - nature.com
Bipolar disorder (BD) has high clinical heterogeneity, frequent psychiatric comorbidities,
and elevated suicide risk. To determine genetic differences between common clinical sub-…

Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications

G Bianchi, RA Kyle, CL Colby… - Blood, The Journal …, 2010 - ashpublications.org
Monoclonal gammopathy of undetermined significance (MGUS) is associated with a long-term
risk of progression to multiple myeloma (MM) or related malignancy. To prevent serious …

[HTML][HTML] Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry

…, D Larson, MY Polley, E Elhaik, M Baird, C Colby… - Blood cancer …, 2018 - nature.com
Multiple myeloma (MM) is two- to three-fold more common in African Americans (AAs) compared
to European Americans (EAs). This striking disparity, one of the highest of any cancer, …